Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week:  
The good — Roche snags FDA nod for subcutaneous cancer immunotherapy 
The bad — Moderna to cut R&amp;D expenses by $1.1B 
The ugly — Teva reaches $80M opioid settlement with Baltimore

[Solutions Spotlight]  Optimizing contamination control in pharma facilities

The Off Script podcast offers in-depth interviews and discussions with industry experts about hot-button topics in pharma, and goes behind the scenes of Pharma Manufacturing’s print and online coverage, which follows the industry’s biggest issues surrounding scale-up, technology innovations, regulations and more

Podbean

Off Script: A Pharma Manufacturing Podcast

Pfizer, Valneva share phase 2 Lyme vax data, IN8bio axes workforce, AstraZeneca employees detained in China [The good, the bad, the ugly]

Roche wins FDA approval for subcutaneous cancer immunotherapy, Moderna to cut $1.1B in R&D expenses, Teva settles $80M opioid case with Baltimore [The good, the bad, the ugly]